AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition – Meet them this November

Talawar Therapeutics Heads to Nasdaq via SPAC Deal to Bankroll Eczema Asset

10 Clinical Trials to Watch Out for in the latter half of 2026 – Read here

Akero execs reunite to advance long-acting psoriasis pill

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Sanofi halts development of troubled immune drug in eczema

Chair’s Opening Remarks

8:25 am - Wednesday 4th November 2026

Harald Schnidar

Chief Executive Officer & President

Scarletred